Table 1.
Interactions with the fixed combination OCs (COCs) in 2013 (total claims n = 682 784)
| Important interacting medications | Number of claims 2013 | % of all COC claims in 2013 |
|---|---|---|
| Enzyme inducers potentially leading to reduced contraceptive effectiveness | ||
| Anti‐epileptic drugs | ||
| Barbiturate/derivatives | 41 | 0.01% |
| Carbamazipine, eslicarbamazepine, oxcarbazepine, Rufinamide | 765 | 0.11% |
| Felbamate | 0 | 0.00% |
| Phenytoin | 55 | 0.01% |
| Primidone | 0 | 0.00% |
| Phenobarbital | 41 | 0.01% |
| Topiramate >200 mg | 101 | 0.01% |
| Lamotrigine >300 mg | 395 | 0.06% |
| Non antiepileptic drugs | ||
| Rifampicin | 3 | <0.01% |
| Aprepitant | 4 | <0.01% |
| Modafinil | 75 | 0.01% |
| Enzyme inhibitors that potentially increase contraceptive levels | ||
| Valproic acid | 1294 | 0.19% |
| Atrovastatin | 1144 | 0.17% |
| Rosuvastatin | 990 | 0.14% |
| Verapamil | 54 | 0.01% |
| Diltiazam | 38 | 0.01% |
| Etorcoxib | 633 | 0.09% |
| Cimetidine | 23 | <0.01% |
| Fluconazole | 1556 | 0.23% |
| Drugs whose effects may be increase by OCP potentially leading to toxicity | ||
| Diazepam + other benzodiazepines | 6044 | 0.89% |
| Prednisone | 1418 | 0.21% |
| Selegiline | 0 | 0.00% |
| Theophylline | 142 | 0.02% |
| Tizanidine | 133 | 0.02% |
| Drugs whose effects may be reduced by OCP potentially leading to reduced clinical effectiveness | ||
| Lamotrigine <300 mg | 1553 | 0.23% |